Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 525

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 525
---
 from $500,000 to $2,000,000 and to provide that, in addition to funding working capital needs, amounts under the Amended and Restated Note may be used for the purposes of making one or more payments to Continental Stock Transfer & Trust Company, a New York limited liability trust company, as Extension Payments (as defined in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 29, 2023, as amended). Other than as set forth above, the terms of the Amended and Restated Note are identical to those of the Working Capital Promissory Note. The issuance of the Amended and Restated Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. As of March 31, 2025 and December 31, 2024, a principal balance of $1,743,499 and $1,731,460, respectively, was outstanding and the fair value of the conversion feature was immaterial. However, due to the conversion feature of the note capped at $1,500,000, the principal balance as of March 31, 2025 is presented as Convertible note payable, with the remaining non -convertibleportion of the note balance shown under Notes payable. On August 26, 2024, the Company issued an unsecured promissory note (the “Bioceres Note”) in the principal amount of $446,000 to Bioceres LLC (“Bioceres”), an indirect shareholder of OmnigenicsAI Corp, the counterparty to the Company’s previously announced business combination. The Bioceres Note bears interest at 20% per annum. The Company shall repay all interest accrued and the principal balance on the date on which the Company consummates F-21 NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS
March 31, 2025 NOTE 6. PROMISSORY NOTE PAYABLE (cont.) its initial business combination. The Bioceres Note is subject to customary events of default, the occurrence of certain of which automatically triggers the unpaid principal balance of the Bioceres Note as well as all accrued interest and all other sums payable with regard to the Note becoming immediately due and payable. As of March 31, 2025, the principal balance outstanding is $446,000 and is shown under Notes payable. On November 7, 2024, the Company issued the unsecured Second Bi